🔎 Trials Near Me

Pradžia › Kartotinė mieloma › Minesota

Kartotinė mieloma klinikiniai tyrimai Minesota

30 tyrimai dėl Kartotinė mieloma ieško dalyvių vietose Minesota.

Miestai Minesota

Oficialus tyrimo tekstas (anglų kalba)

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Mayo Clinic Health System-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06630104

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

  • Mayo Clinic in Rochester, Rochester
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07850284

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • University Of Minnesota Medical Center, Minneapolis
  • Mayo Clinic, Rochester
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07518186

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic Rochester, Rochester
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07258511

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  • Mayo Clinic, Rochester
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07393282

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Mayo Clinic Rochester, Rochester
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05201781

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  • Minnesota Oncology - Minneapolis Clinic /ID# 278720, Minneapolis
  • Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07095452

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06465316

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Minnesota, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT06297226

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic Rochester, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT06375044

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-26 · NCT06940297

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • Minnesota Oncology - Burnsville, Burnsville
  • Cambridge Medical Center, Cambridge
  • Minnesota Oncology Hematology PA-Chaska, Chaska
  • ir dar 24
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

  • Mayo Clinic - Transplant Center - Rochester, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Minneapolis
  • Research Site, Rochester
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05850234

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Mayo Clinic - Minnesota, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-06 · NCT07284758

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Minnesota, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-16 · NCT06121843

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic - Rochester /ID# 251164, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT05650632

Integrated Cancer Repository for Cancer Research

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health-St. Joseph's Medical Center, Brainerd
  • Essentia Health - Duluth Clinic, Duluth
  • ir dar 2
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 19 iki 110 · Visoms lytims · Atnaujinta 2026-06-29 · NCT02012699

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-25 · NCT06785415

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

  • Masonic Cancer Center at University of Minnesota, Minneapolis
Renkami dalyviai2 fazė
Iki 60 metų · Visoms lytims · Atnaujinta 2026-06-25 · NCT03314974

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health - Baxter Clinic, Baxter
  • Sanford Joe Lueken Cancer Center, Bemidji
  • ir dar 40
Renkami dalyviai3 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-06-10 · NCT05561387

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

  • University of Minnesota - Masonic Cancer Center, Minneapolis
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-05 · NCT03858205

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  • Minnesota Oncology Hematology, Minneapolis
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-22 · NCT05972135

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai
Amžius 65 ir vyresni · Visoms lytims · Atnaujinta 2026-04-13 · NCT06145581

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Allina Health Cancer Institute, Minneapolis
  • Mayo Clinic, Rochester
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 40 ir vyresni · Visoms lytims · Atnaujinta 2026-01-20 · NCT05366881

Family Study of Lymphoproliferative Disorders

  • Mayo Clinic, Rochester
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2025-10-14 · NCT00626496

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  • University of Minnesota, Minneapolis
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-06-03 · NCT06119685

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

  • Center for International Blood and Marrow Transplant Research, Minneapolis
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2023-08-30 · NCT03127761

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.